Actively Recruiting
Ketamine Infusion as a Method of Cerebral Protection in Children
Led by Kemerovo State Medical University · Updated on 2024-07-29
196
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is devoted to the use of ketamine infusion in a subanesthetic dose in the postoperative period in children after surgical correction of congenital heart defects in children.
CONDITIONS
Official Title
Ketamine Infusion as a Method of Cerebral Protection in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 1 to 60 months
- Body weight from 3.5 to 20 kg
- Planned surgical correction of atrial or ventricular septal defect using cardiopulmonary bypass
- Signed informed consent from the child's legal representative
You will not qualify if you...
- No informed consent from patient or parents
- Emergency or urgent surgery
- Clinically significant anemia
- Hypothermia during operation or desaturation episodes in perioperative period
- Other congenital heart diseases besides atrial or ventricular septal defect
- History of central nervous system diseases
- Installed pacemaker
- Hemodynamic instability requiring preoperative support
- History or perioperative cerebrovascular accidents
- Severe concomitant diseases affecting mental or physical condition
- Acute or worsening chronic infection in perioperative period
- Autoimmune diseases
- Malignant tumors
- Surgical complications in postoperative period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Artem Ivkin
Kemerovo, Please Select, Russia, 650066
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here